中国基金报记者 晨曦 ST惠伦，罚单正式落地！ 1月12日晚间，ST惠伦发布公告称，其公司及相关当事人收到《中国证券监督管理委员会广东监管局行 政处罚决定书》。ST惠伦及相关人员合计被处罚1140万元。 来看详情—— 定期报告存在重大遗漏、虚假记载 2020年，惠伦晶体以采购设备及材料、预付工程款等名义向东莞市某科技有限公司等7家公司支出款 项，并最终划转至控股股东新疆惠伦及公司实际控制人赵积清本人等关联方银行账户，用于归还新疆惠 伦股权质押款及赵积清个人借款。 上述关联方非经营性资金往来构成关联方对公司的资金占用，2020年累计发生额为2833万元，期末余额 为2663万元，资金占用发生额占惠伦晶体2020年年度报告披露净资产的5.12%。根据相关规定，上述事 项应当在定期报告中披露。而惠伦晶体在2020年年度报告中未予披露，构成重大遗漏。 二是虚增成本费用、虚增收入，2021年、2022年年度报告存在虚假记载。 2021年、2022年，惠伦晶体存在虚构采购业务、虚构销售业务以及未按实际情况确认收入等情形，分别 虚增营业收入2548.99万元、6233.36万元，占当期披露营业收入的3.89%、15.79% ...

截至2026年1月12日收盘，ST惠伦(300460)报收于9.02元，上涨10.27%，换手率11.33%，成交量31.81万 手，成交额2.82亿元。 广东惠伦晶体科技股份有限公司及实际控制人赵积清因涉嫌信息披露违法违规，收到中国证监会广东监 管局下发的《行政处罚决定书》。公司未按规定披露2020年资金占用事项，导致年度报告存在重大遗 漏；2021年、2022年通过虚构采购与销售业务等方式虚增收入、成本费用，导致年度报告存在虚假记 载。监管机构对公司责令改正，给予警告，并处以300万元罚款；对赵积清处以400万元罚款，其他相关 责任人亦被处以警告及罚款。公司表示已归还占用资金，生产经营正常，且该处罚不触及重大违法强制 退市情形。 当日关注点 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 交易信息汇总资金流向 来自交易信息汇总：1月12日主力资金净流入1862.08万元，显示主力对个股短期关注度提升。 来自公司公告汇总：ST惠伦因2020至2022年信息披露违规被证监会处罚，公司及实控人合计被罚 700万元。 1月12日主力资金 ...

【导读】ST惠伦公布行政处罚决定书，公司及相关人员合计被罚1140万元 ST惠伦，罚单正式落地！ 1月12日晚间，ST惠伦发布公告称，其公司及相关当事人收到《中国证券监督管理委员会广东监管局行政处罚决定书》。ST惠伦及相关 人员合计被处罚1140万元。 来看详情—— 一是未按规定披露资金占用事项，2020年年度报告存在重大遗漏。 2020年，惠伦晶体以采购设备及材料、预付工程款等名义向东莞市某科技有限公司等7家公司支出款项，并最终划转至控股股东新疆惠 伦及公司实际控制人赵积清本人等关联方银行账户，用于归还新疆惠伦股权质押款及赵积清个人借款。 上述关联方非经营性资金往来构成关联方对公司的资金占用，2020年累计发生额为2833万元，期末余额为2663万元，资金占用发生额占 惠伦晶体2020年年度报告披露净资产的5.12%。根据相关规定，上述事项应当在定期报告中披露。而惠伦晶体在2020年年度报告中未予 披露，构成重大遗漏。 二是虚增成本费用、虚增收入，2021年、2022年年度报告存在虚假记载。 2021年、2022年，惠伦晶体存在虚构采购业务、虚构销售业务以及未按实际情况确认收入等情形，分别虚增营业收入254 ...

Group 1 - CITIC Securities maintains a "Buy" rating for Huahong Semiconductor (01347.HK) with a target price of HKD 100, highlighting its leading position in specialty process wafer foundry and strong growth potential from capacity expansion and acquisitions [1] - CITIC Securities also maintains a "Buy" rating for SiHuan Pharmaceutical (00460.HK) with a target price of HKD 1.6, noting rapid growth in its medical aesthetic products and strong sales performance of new regenerative products [1] - GF Securities maintains a "Buy" rating for Yum China (09987.HK) with a target price of HKD 453.62, citing improved same-store sales and growth driven by new product iterations and marketing strategies [1] Group 2 - GF Securities initiates coverage on Laoputang Gold (06181.HK) with a "Buy" rating and a target price of HKD 775.64, emphasizing its leading position in handcrafted gold jewelry and strong growth potential from store expansion [2] - GF Securities initiates coverage on Yue Yuen Industrial (00551.HK) with a "Buy" rating and a target price of HKD 19.99, highlighting its status as the largest athletic shoe manufacturer and expected performance recovery [3] Group 3 - Cinda International maintains a "Buy" rating for Hesai Technology (02525.HK), noting its leadership in the global LiDAR market and significant growth in production and market share [4] - Zhongtai Securities initiates coverage on China Resources Land (01109.HK) with an "Accumulate" rating, reporting strong revenue and profit growth along with a healthy financial structure [5] Group 4 - First Shanghai initiates coverage on Jaxin International Resources (03858.HK) with a "Buy" rating and a target price of HKD 82.4, highlighting its world-class tungsten resources and strong profit growth potential [6] - Kaiyuan Securities initiates coverage on Beautiful Pastoral Medical Health (02373.HK) with a "Buy" rating, emphasizing its differentiated business model and effective customer acquisition strategies [7] Group 5 - CICC maintains an "Outperform" rating for Standard Chartered Group (02888.HK), noting better-than-expected Q2 2025 performance driven by significant growth in non-interest income [8]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 四環醫藥控股集團有限公司 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00460 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 100,000,000,000 | HKD | | 0.01 | HKD | | 1,000,000 ...

Group 1 - The core viewpoint of the news is that Hong Kong's innovative drug concept stocks experienced a collective rise, indicating positive market sentiment in the pharmaceutical sector [1] Group 2 - Jingtai Holdings (02228) saw an increase of 6.13%, with a latest price of 10.040 and a total market capitalization of 43.206 billion [2] - Hengrui Medicine (01276) rose by 4.63%, with a latest price of 74.550 and a total market capitalization of 494.803 billion [2] - SiHuan Pharmaceutical (00460) increased by 4.07%, with a latest price of 1.280 and a total market capitalization of 11.707 billion [2] - Innovent Biologics (01801) experienced a rise of 3.34%, with a latest price of 78.800 and a total market capitalization of 135.599 billion [2] - WuXi Biologics (02269) increased by 3.18%, with a latest price of 32.440 and a total market capitalization of 133.916 billion [2] - China National Pharmaceutical Group (01177) rose by 3.07%, with a latest price of 6.370 and a total market capitalization of 119.506 billion [2] - BeiGene (06160) saw an increase of 2.68%, with a latest price of 184.100 and a total market capitalization of 283.639 billion [2] - Kingstar Bio (01548) rose by 2.66%, with a latest price of 12.750 and a total market capitalization of 27.874 billion [2] - Genscript Biotech (01952) increased by 2.49%, with a latest price of 37.900 and a total market capitalization of 13.4 billion [2] - WuXi AppTec (02359) saw a rise of 2.13%, with a latest price of 100.800 and a total market capitalization of 300.763 billion [2]

Group 1 - The core viewpoint of the article highlights the significant rise in Hong Kong's innovative drug concept stocks, indicating a positive trend in the sector [2] - Jingtai Holdings experienced a surge of over 6%, reflecting strong investor interest and confidence in the company [2] - Hengrui Medicine saw an increase of over 5%, suggesting robust performance and market positioning [2] - Four Seasons Pharmaceutical rose by more than 4%, indicating a favorable market response [2] - Innovent Biologics and WuXi Biologics both increased by over 3%, showcasing the overall strength of the innovative drug sector [2] - BeiGene's stock rose by over 2%, further contributing to the positive sentiment in the market [2]

Summary of Key Points Core Viewpoint - On December 29, 55 Hong Kong-listed companies conducted share buybacks, totaling 37.9 million shares and an aggregate amount of HKD 999 million [1][2]. Group 1: Major Companies Involved in Buybacks - Tencent Holdings repurchased 1.057 million shares for HKD 636 million, with a yearly total buyback amount of HKD 78.765 billion [1][2]. - Xiaomi Group-W bought back 3.9 million shares for HKD 151 million, with a total buyback amount of HKD 6.136 billion for the year [1][2]. - China COSCO Shipping Holdings repurchased 3.46 million shares for HKD 47.9 million, with a total buyback amount of HKD 6.866 billion for the year [1][2]. Group 2: Buyback Statistics - The highest buyback amount on December 29 was from Tencent Holdings at HKD 636 million, followed by Xiaomi Group-W at HKD 151 million [1][2]. - The largest number of shares repurchased on December 29 was by Four Seasons Medicine, with 8 million shares, followed by Xiaomi Group-W and China COSCO Shipping Holdings with 3.9 million and 3.46 million shares, respectively [1][2]. Group 3: Additional Companies and Their Buyback Data - Kingsoft repurchased 713,600 shares for HKD 20 million, with a total buyback amount of HKD 33.465 million for the year [2]. - Kuaishou-W bought back 310,000 shares for HKD 20 million, with a total buyback amount of HKD 306.840 million for the year [2]. - Other notable companies include Miniso Group, which repurchased 320,600 shares for HKD 1.195 million, and Four Seasons Medicine, which had a total buyback amount of HKD 15.332 million for the year [2][3].

格隆汇勾股大数据显示，腾讯控股(00700)、小米集团-W(01810)、三花智控(02050)、中远海控(01919)、 金山软件(03888)、快手-W(01024)、巨子生物(02367)、碧桂园服务(06098)、名创优品(09896)、四环医 药(00460)、明源云(00909)、津上机床中国(01651)、多点数智(02586)、科济药业-B(02171)、富智康集团 (02038)、趣致集团(00917)、汇通达网络(09878)、海吉亚医疗(06078)、心玮医疗-B(06609)、德康农牧 (02419)、绿城服务(02869)、捷利交易宝(08017)、歌礼制药-B(01672)、VITASOY INT'L(00345)、同道猎 聘(06100)、海尔智家(06690)、荃信生物-B(02509)、知行科技(01274)、连连数字(02598)、昊海生物科技 (06826)、锅圈(02517)、叮当健康(09886)、天伦燃气(01600)、中远海发(02866)、信利国际(00732)、绿茶 集团(06831)、思派健康(00314)、希玛医疗(03309)、枫叶教育(01317)、北 ...

四环医药(00460)发布公告，于2025年12月29日斥资1000.88万港元回购800万股。 ...